Houston, TX (May 2020) – Pulmotect, Inc., a clinical-stage biotechnology company, has received approval from the U.S. Food & Drug Administration (FDA) to initiate two COVID-19 Phase-2 clinical trials of its innate immune-stimulating drug PUL-042. The Company plans to start accrual within the next week at up to twenty U.S. sites. The trials are for the prevention of infection with SARS-CoV-2 and the prevention of disease progression in patients with early COVID-19 disease. Funding for the trials came from the final closing of the Company’s offering of Series B Preferred stock in March.
Recently, in research published in the Immunity, researchers from University College London in the United Kingdom revealed that a special type of immune cells can be activated to kill cancerous cells through research on mice. Related research may give hope for the development of new types of anticancer therapy.
Nowadays, the brightest innovations usually happen at the intersection of different disciplines and technologies. A recent scientific achievement by Dr. Carsten Krieg, a researcher at Hollings Cancer Center (HCC), Medical University of South Carolina, is not an exception to this observation.
With an ambitious goal in mind to advance the field of cancer immunotherapy, Dr. Krieg combines a very powerful analytical technique -- mass cytometry, with artificial intelligence (AI), machine learning and bioinformatics tools to visualize the obtained experimental data and have a bird’s-eye view of the immune system.
Immunotherapies are hot property. Immuno-oncology is the crown jewel. But the road to riches, and more importantly cancer cures, is now crowded and full of potholes. Drug hunters need to look ahead, beyond the discovery process itself, to the reality of the many impediments that will confront drug candidates as they proceed towards the clinic in today's landscape. Here, I present three insights from current events, the third one taking a contrarian position.